Quinolone Resistance Mechanisms in Staphylococcus aureus. Quinolone antimicrobials act on two topoisomerases and are used widely in human infections. Their use for common S. aureus infections has been limited by emerging resistance. Resistance mechanisms include altered topoisomerases and increased expression of multidrug resistance (MDR) efflux pumps. Defining these mechanisms is key to strategies to avoid resistance. Long-term objectives of the project are to use quinolones and resistant mutants as a model system to study the control and function of topoisomerases and efflux pumps found in many bacteria.
Specific aims are (1) to define the roles of novel mutations in topoisomerase IV in effecting resistance and altering enzyme function. Mutant enzymes will be purified and studied for their catalytic functions and binding of DNA and quinolones as well as formation of quinolone-induced DNA cleavage.
Aim (2) is to identify the sites of quinolone interaction with complexes of topoisomerase IV, DNA, and quinolone using x-ray crystallography of wildtype and mutant enzymes complexed with DNA and drug.
Aim (3) is to identify the mechanism by which the NorR protein regulates expression of the Nora efflux pump and possibly other related pumps using DNA footprinting with norA promoter DNA and purified NorR. We will also perform transcriptional profiling of the expression of genes encoding efflux pumps with DNA microarrays hybridized with RNA prepared from strains with mutations in norR and arlS, both of which affect norA expression.
Aim (4) is to identify additional factors regulating norA expression by purification of a 28-kd protein that in addition to NorR binds upstream of norA, identification of the gene encoding, and generating mutants in this gene.
Aim (5) is to identify the complement of multidrug resistance pumps and analyze their expression in an abscess model. This work will be done by analysis of genes related to those of known MDR pumps and their regulators and selected cloning and overexpression of these genes in S. aureus. Overall patterns of expression of the genes will be compared by transcriptional profiling in DNA microarrays using RNA prepared from bacteria surviving in a subcutaneous abscess in rats and RNA from bacteria grown in vitro.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI023988-17
Application #
6855078
Study Section
Special Emphasis Panel (ZRG1-BM-1 (02))
Program Officer
Peters, Kent
Project Start
1986-09-01
Project End
2008-03-31
Budget Start
2005-04-01
Budget End
2006-03-31
Support Year
17
Fiscal Year
2005
Total Cost
$389,250
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Hooper, David C; Jacoby, George A (2016) Topoisomerase Inhibitors: Fluoroquinolone Mechanisms of Action and Resistance. Cold Spring Harb Perspect Med 6:
Hooper, David C; Jacoby, George A (2015) Mechanisms of drug resistance: quinolone resistance. Ann N Y Acad Sci 1354:12-31
Jacoby, George; Cattoir, Vincent; Hooper, David et al. (2008) qnr Gene nomenclature. Antimicrob Agents Chemother 52:2297-9
Truong-Bolduc, Que Chi; Hooper, David C (2007) The transcriptional regulators NorG and MgrA modulate resistance to both quinolones and beta-lactams in Staphylococcus aureus. J Bacteriol 189:2996-3005
Strahilevitz, Jacob; Onodera, Yoshikuni; Hooper, David C (2006) An improved expression plasmid for affinity purification of Staphylococcus aureus gyrase A subunit. Protein Expr Purif 47:10-5
Strahilevitz, Jacob; Robicsek, Ari; Hooper, David C (2006) Role of the extended alpha4 domain of Staphylococcus aureus gyrase A protein in determining low sensitivity to quinolones. Antimicrob Agents Chemother 50:600-6
Truong-Bolduc, Que Chi; Strahilevitz, Jacob; Hooper, David C (2006) NorC, a new efflux pump regulated by MgrA of Staphylococcus aureus. Antimicrob Agents Chemother 50:1104-7
Strahilevitz, Jacob; Hooper, David C (2005) Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin. Antimicrob Agents Chemother 49:1949-56
Strahilevitz, Jacob; Truong-Bolduc, Que Chi; Hooper, David C (2005) DX-619, a novel des-fluoro(6) quinolone manifesting low frequency of selection of resistant Staphylococcus aureus mutants: quinolone resistance beyond modification of type II topoisomerases. Antimicrob Agents Chemother 49:5051-7
Hooper, David C (2005) Efflux pumps and nosocomial antibiotic resistance: a primer for hospital epidemiologists. Clin Infect Dis 40:1811-7

Showing the most recent 10 out of 43 publications